Why the study?
AF prevalence increases with age, with over 80% of US adults with AF aged 65 years or older, prompting a comparison of clinical outcomes between DOACs and warfarin in elderly NVAF patients.
Do direct oral anticoagulants improve clinical outcomes compared to warfarin in elderly patients with non-valvular atrial fibrillation?
Do direct oral anticoagulants improve clinical outcomes compared to warfarin in elderly patients with non-valvular atrial fibrillation?
In elderly Medicare patients with non-valvular AF, apixaban demonstrated superior efficacy and safety compared to warfarin, whereas rivaroxaban reduced stroke but increased major bleeding, and dabigatran reduced bleeding with similar stroke risk.
Answers are grounded in this paper and cite their sources.
May support DOAC preference in elderly NVAF; leaves open need for randomized confirmation on stroke, bleeding, and NCO.
Atrial fibrillation (AF) prevalence increases with age; > 80% of US adults with AF are aged ≥ 65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net clinical outcome (NCO), and major adverse cardiac events (MACE) among elderly non-valvular AF (NVAF) Medicare patients prescribed direct oral anticoagulants (DOACs) VS warfarin. NVAF patients aged ≥ 65 years who initiated DOACs (apixaban, dabigatran, and rivaroxaban) or warfarin were selected from 01JAN2013-31DEC2015 in CMS Medicare data. Propensity score matching was used to balance DOAC and warfarin cohorts. Cox proportional hazards models estimated the risk of stroke/SE, MB, NCO, and MACE. 37,525 apixaban-warfarin, 18,131 dabigatran-warfarin, and 55,359 rivaroxaban-warfarin pairs were included. Compared to warfarin, apixaban (HR: 0.69; 95% CI 0.59-0.81) and rivaroxaban (HR: 0.82; 95% CI 0.73-0.91) had lower risk of stroke/SE, and dabigatran (HR: 0.88; 95% CI 0.72-1.07) had similar risk of stroke/SE. Apixaban (MB: HR: 0.61; 95% CI 0.57-0.67; NCO: HR: 0.64; 95% CI 0.60-0.69) and dabigatran (MB: HR: 0.79; 95% CI 0.71-0.89; NCO: HR: 0.84; 95% CI 0.76-0.93) had lower risk of MB and NCO, and rivaroxaban had higher risk of MB (HR: 1.08; 95% CI 1.02-1.14) and similar risk of NCO (HR: 1.04; 95% CI 0.99-1.09). Compared to warfarin, apixaban had a lower risk for stroke/SE, MB, and NCO; dabigatran had a lower risk of MB and NCO; and rivaroxaban had a lower risk of stroke/SE but higher risk of MB. All DOACs had lower risk of MACE compared to warfarin.
No takes yet. Share an insight, caveat, or question.
Amin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: